Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Documenti analoghi

• Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.
  di: Ellis, M N, et al.
  Pubblicazione: (1989)
• Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
  di: Spector, T, et al.
  Pubblicazione: (1992)
• 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
  di: Spector, T, et al.
  Pubblicazione: (1989)
• Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.
  di: Field, H J
  Pubblicazione: (1982)
• Development of Clinical Resistance to Acyclovir in Herpes Simplex Virus-Infected Mice Receiving Oral Therapy
  di: Field, Hugh J.
  Pubblicazione: (1982)